Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.

Long‐term biological therapy likely needed in perianal Crohn’s disease management

01 Nov 2019

Discontinuation of antitumour necrosis factor (anti-TNF) therapy for perianal Crohn’s disease is highly likely to lead to relapse, with some patients even requiring defunctioning surgery, according to a study conducted across Asia.

The study population comprised 78 perianal CD patients from Hong Kong, Shanghai, Taiwan, Malaysia, Thailand and Singapore. All patients were treated with anti-TNF therapy with subsequent discontinuation.

A total of 44 patients (56.4 percent) relapsed after a median follow-up of 89 months. Relapse was defined as increased fistula drainage or recurrence of previously healed fistula after discontinuing anti-TNF therapy.

Cumulative probabilities of perianal CD relapse were 50.8 percent at 12 months, 72.6 percent at 36 months and 78.0 percent at 60 months. In multivariable Cox regression models, younger age at diagnosis of CD was associated with a 4-percent increased likelihood of developing perianal CD relapse (adjusted hazard ratio [HR], 1.04, 95 percent confidence interval [CI], 1.01–1.09; p=0.04).

Retreatment with anti-TNF induced remission in 24 of 29 patients (82.8 percent) with perianal CD relapse. Twelve patients (27.3 percent) needed defunctioning surgery, while one (2.3 percent) required proctectomy. Thiopurine maintenance had no beneficial effect on the risk of relapse (HR, 1.10, 95 percent CI, 0.58–2.12; p=0.77).

Five of the 17 patients (35.3 percent) who achieved radiological remission developed relapse after stopping anti-TNF therapy after a median of 6 months.

The findings highlight the importance of radiological assessment of perianal CD before stopping anti-TNF therapy, and that long-term biological therapy is most likely needed, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.